Pierre Beaurang - 10 Aug 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Business Officer
Signature
/s/ Christine Ring, as Attorney-in-Fact for Pierre Beaurang
Issuer symbol
NRIX
Transactions as of
10 Aug 2021
Net transactions value
-$215,601
Form type
4
Filing time
11 Aug 2021, 18:20:52 UTC
Previous filing
12 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $8,325 +7,500 +173% $1.11* 11,830 10 Aug 2021 Direct F1
transaction NRIX Common Stock Sale $167,129 -5,620 -48% $29.74 6,210 10 Aug 2021 Direct F1, F2
transaction NRIX Common Stock Sale $56,797 -1,880 -30% $30.21 4,330 10 Aug 2021 Direct F1, F3
holding NRIX Common Stock 116,666 10 Aug 2021 By Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -7,500 -53% $0.000000 6,562 10 Aug 2021 Common Stock 7,500 $1.11 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $29.07 and the highest price at which shares were sold was $30.06. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 Represents the weighted average sale price. The lowest price at which shares were sold was $30.07 and the highest price at which shares were sold was $30.34.
F4 The Reporting Person is a trustee of the Beaurang-Sligh Family Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F5 The option is fully vested.